Date published: 2026-7-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

v-SNARE Vti1a CRISPR/Cas9 KO Plasmid (h): sc-406891

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • v-SNARE Vti1a CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the v-SNARE Vti1a genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • v-SNARE Vti1a HDR Plasmid (h) (sc-406891-HDR) is recommended for co-transfection with v-SNARE Vti1a CRISPR/Cas9 KO Plasmid (h) to enable selection of successfully edited cells through HDR-mediated integration of a puromycin resistance cassette and RFP reporter gene
  • v-SNARE Vti1a HDR Plasmid (h) is a pool of plasmids, each containing a homology-directed repair (HDR) template corresponding to the gRNA target sites in the v-SNARE Vti1a CRISPR/Cas9 KO Plasmid (h)
  • Each HDR plasmid contains two ~800 bp homology arms flanking the puromycin resistance and RFP cassettes, designed to bind genomic DNA sequences surrounding the Cas9-induced double-strand break site and facilitate precise HDR-mediated integration
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: v-SNARE Vti1a Antibody (45): sc-136117
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    v-SNARE Vti1a CRISPR/Cas9 KO Plasmid (h)

    sc-406891
    20 µg
    $397.00

    v-SNARE Vti1a HDR Plasmid (h)

    sc-406891-HDR
    20 µg
    $445.00

    Overview

    VTI1A encodes the vesicle SNARE protein v-SNARE Vti1a, a core component of membrane fusion machinery that helps drive cargo trafficking between endosomes, the trans-Golgi network, and lysosome-related compartments. By pairing with cognate t-SNAREs, Vti1a supports vesicle docking and fusion events that coordinate endosomal sorting, autophagy-linked membrane dynamics, and maintenance of organelle identity. Disruption of SNARE-mediated trafficking can alter receptor turnover, proteostasis, and secretory flux, processes frequently leveraged to study cellular stress responses and signaling homeostasis. VTI1A has also been investigated in the context of altered intracellular transport observed in cancer and neurobiology-focused models, where trafficking rewiring can influence growth-factor signaling and synaptic vesicle pathways.

    v-SNARE Vti1a CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the VTI1A gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the VTI1A locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.

    When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.

    Homology-Directed Repair (HDR) Donor — Puromycin Cassette with RFP Reporter

    For applications requiring confirmed, selectable knockout clones, v-SNARE Vti1a HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined VTI1A target site.
    When co-transfected with v-SNARE Vti1a CRISPR/Cas9 KO Plasmid (h):

    • The PuroR-RFP cassette integrates at the Cas9 cut site via HDR, disrupting the VTI1A open reading frame.
    • RFP fluorescence provides an immediate visual indicator of successful integration, enabling fluorescence-based identification or sorting of edited cells prior to or alongside puromycin selection.
    • Successfully edited cells are confirmed through puromycin resistance, substantially reducing clone screening burden.
    • This selection strategy is ideal for generating stable, clonal KO cell lines for downstream functional studies, drug screening, or model development.

    Cre-lox Cassette Removal System

    The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the VTI1A locus and eliminating potential confounding effects on downstream assays.
    This two-step approach:

    • Minimizes disruption to local chromatin architecture and neighboring regulatory elements
    • Restores a near-native genomic context at the edited locus
    • Enables reuse of the puromycin selection strategy in the same cell line for additional edits

    Key Features

    • gRNA targeting VTI1A exon(s) critical for v-SNARE Vti1a function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • HDR donor with puromycin resistance for positive clone selection
    • loxP-flanked PuroR cassette with Cre recombinase vector for seamless marker removal
    • Supplied ready to use for delivery by transfection

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.